Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Delivers robust earnings performance, successfully navigating a dynamic environment
The company has reported total income of Rs. 628.4 crores during the period ended March 31, 2025
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
The closing of the Block Acquisition is now expected to be completed by Q3 2025
Bayer expects 2025 to be the most difficult year of its turnaround
For the financial year ended March 31, 2025, Thyrocare has reported total income of Rs.702.18 crores
Multiple studies show the combination potential of vedotin antibody-drug conjugates (ADCs) with pembrolizumab, including the first Phase 1 data in thoracic cancers for two first-in-class ADCs
Syngene reported revenue growth of 11% year-on-year, and 8% sequentially crossing the Rs. 1,000 Cr in a quarter threshold for the first time
Subscribe To Our Newsletter & Stay Updated
